- Harrow Enters into Commercialization Agreement with Samsung Bioepis for . . .
Harrow, Inc (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market
- Harrow
Harrow, a growing leader in the North American ophthalmic pharmaceutical market, is dedicated to delivering innovative, accessible, and affordable eyecare solutions
- Harrow Appoints Mike Biega as Vice President of Investor Relations and . . .
Harrow, Inc (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market
- Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial . . .
Harrow, Inc (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market
- Products - Harrow
Harrow owns an FDA-Registered 503B Outsourcing Facility and a patient-specific 503A pharmacy
- Harrow Announces Second Quarter 2024 Financial Results
“The second quarter of 2024 marked a financial and operational turning point for Harrow, with revenues surging 46% compared to the same quarter last year and 42% over the previous quarter,” said Mark L Baum, Chief Executive Officer of Harrow
- Harrow to Report First Quarter 2025 Financial Results After Market . . .
Harrow, Inc (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market
- Harrow Announces First-Quarter 2025 Financial Results
Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year For more information about Harrow, please visit harrow com
|